14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NEXR vs AKAN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NEXR Captures Overall Composite Edge (31.0 SELL vs 43.8 HOLD), While AKAN Leads 4–1 on Growth & Valuation Pillars
NEXR Overall Winner
6-Pillar Tally: NEXR 1 – 4 AKAN (1 Tie)
Matrix Metrics: NEXR 1 – 7 AKAN
As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. NEXR trades at $1.38 (N/M Forward P/E, N/A operating margin) versus AKAN at $2.00 (N/M Forward P/E, -1254.5% operating margin).
Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY).
Technical & Structure Timing Caution: NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.6); meanwhile AKAN is in a Breakdown options structure phase (RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEXR vs AKAN. Trailing 12-month operating profitability (NEXR N/A vs AKAN -1254.5%) and valuation multiples (NEXR N/M vs AKAN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
AKAN Moat ProfileCyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.2M market capitalization and -1254.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NEXR vs AKAN Key Questions & Quantitative Answers
As of Nov 16, 2026, NEXR (NEXR) captures the overall head-to-head institutional edge over Akanda Corp. Common Shares (AKAN) on higher Unified Composite conviction (31.0/100 SELL vs. 43.8/100 HOLD) after splitting the core matrix 1–7 (led by Options & Positioning), while AKAN wins 4–1 across the 6-pillar growth and valuation breakdown. NEXR trades at $1.38 (N/M Forward P/E, N/A operating margin) versus AKAN at $2.00 (N/M Forward P/E, -1254.5% operating margin). Composite vs. Pillar Nuance: While AKAN currently prints a higher short-term Unified Composite Score (43.8/100 HOLD vs. NEXR 31.0/100 SELL), NEXR captures the overall institutional head-to-head verdict (1–7 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (N/A vs. -1254.5% operating margin) and revenue trajectory (N/A vs. +21.9% YoY). Technical & Structure Timing Caution: NEXR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.6); meanwhile AKAN is in a Breakdown options structure phase (RSI 65.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AKAN leads the Growth & Scale pillar: NEXR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with AKAN at +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin). On trailing 12-month operating scale, NEXR generates N/A in USD-normalized revenue versus $662,469 for AKAN. In operating R&D and SG&A reinvestment, NEXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKAN.
AKAN screens cheaper on headline valuation multiples. NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEXR (N/A ROE) versus AKAN (-60.9% ROE) capital efficiency.
In options market volatility and institutional positioning, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk). By comparison, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (5.43β · 428% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.